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Abstract 
Targeted nanomedicines offer many advantages over macromolecular therapeutics that rely only on passive 
accumulation within the tumour environment. The aim of this work was to investigate the in vivo anticancer 
efficiency of polymeric nanomedicines that were conjugated with peptide aptamers that show high affinity for 
receptors on many cancer cells. In order to assess the ability for the nanomedicine to treat cancer and 
investigate how structure affected the behavior of the nanomedicine, three imaging modalities were utilized, 
including in vivo optical imaging, multispectral optoacoustic tomography (MSOT) and ex vivo confocal 
microscopy. An 8-mer (A8) or 13-mer (A13) peptide aptamer that have been shown to exhibit high affinity for 
heat shock protein 70 (HSP70) was covalently-bound to hyperbranched polymer (HBP) nanoparticles with the 
purpose of both cellular targeting, as well as the potential to impart some level of chemo-sensitization to the 
cells. Furthermore, doxorubicin was bound to the polymeric carrier as the anticancer drug, and Cyanine-5.5 
(Cy5.5) was incorporated into the polymer as a monomeric fluorophore to aid in monitoring the behavior of 
the nanomedicine.  Enhanced tumour regression was observed in nude mice bearing MDA-MB-468 xenografts 
when the nanocarriers were targeted using the peptide ligands, compared to control groups treated with free 
DOX or HBP without aptamer. The accumulated DOX level in solid tumours was 5.5 times higher in mice 
treated with the targeted therapeutic, than mice treated with free DOX, and 2.6 times higher than the 
untargeted nanomedicine that relied only on passive accumulation. The results suggest that aptamer-targeted 
therapeutics have great potential for improving accumulation of nanomedicines in tumours for therapy. 
Key words: peptide aptamers, chemo-sensitization, Multispectral Optoacoustic Tomography (MSOT), nanomedicine 
Introduction 
Breast cancer, which involves the abnormal 
growth of cells lining the breast lobules or ducts, is the 
most frequently diagnosed cancer and a leading cause 
of cancer-related deaths in women world-wide.[1] At 
present, small molecules such as doxorubicin and 
other chemotherapeutic drugs are used as first-line 
treatments for the disease. However, due to poor 
tissue selectivity, these chemotherapeutic drugs 
consistently result in serious side effects, such as 
cardiotoxicity caused by doxorubicin.[2-3]  It has also 
been observed that during the course of treatment, 
many tumours develop multidrug resistance (MDR) 
which is a major impediment to current cancer 
therapies.[4] In order to address these problems, 
nanoparticles have been widely investigated as an 
alternative formulation for drug delivery in cancer 
treatment.[5],[6] One particular variety of 
multifunctional nanoparticles combining therapeutic, 
diagnostic, and sensing modalities in one 
nanostructure, a so-called theranostic, is a promising 
concept in cancer therapy.[7-12] 








assisting in protein stabilization and translocation of 
polypeptides across the cell membrane is 
indispensable for cell survival under conditions of 
stress.[13] It has been found to be over-expressed in 
many types of cancers including breast cancer.[14-17] 
Therefore, targeting and potentially inhibiting HSP70 
is a promising strategy in cancer therapy.[18] Rérole 
and coworkers have investigated a library of small 
peptide-aptamers and found a number of potential 
candidates that exhibited high affinity for HSP70, as 
well as enhanced chemo-sensitization.[19] Thus, these 
aptamers show significant potential as a therapeutic 
strategy for overcoming multidrug resistance.  
  From our previous work, we successfully 
developed a hyperbranched polymeric theranostic 
nanoparticle bearing an A8 aptamer (as defined by 
Rérole et al. [19]) as a targeting moiety, DOX as 
chemotherapeutic agent via a pH degradable 
hydrazone bond and a fluorescent dye (Cy-5) as a 
diagnostic and imaging agent.[20], [21]  This study 
also demonstrated enhanced accumulation of 
polymers bearing an 8-mer aptamer within solid 
tumours in mice compared to the untargeted 
analogue. However, no studies have demonstrated 
the effect of these aptamers on the therapeutic efficacy 
of the nanoparticles. Motivated by the promising 
enhancement in accumulation of the nanomedicines 
in tumour tissue, here we investigate the therapeutic 
efficiency of this polymeric theranostic delivery 
system for two different peptide aptamers as potential 
targeting ligands, A8 and A13 (Figure 1).  
 






















































































































































































The main focus was to assess whether the two 
peptides exhibited improved targeting of 
nanomedicines leading to enhanced therapeutic 
efficacy, while minimizing undesirable side-effects; 
such an assessment not only looked at the tumour 
regression, but also on the ability for the 
nanomedicine and/or drug molecules to diffuse 
through tumour tissue. A secondary motivator was to 
assess whether one peptide was more efficient than 
the other at increasing tissue accumulation when 
attached to the nanomedicine, since Rérole et al.[19] 
showed varying efficacy for these two peptides. We 
were able to independently track the biodistribution 
and intracellular distribution of both the DOX and the 
hyperbranched polymer nanocarrier during in vivo 
analysis using optical imaging and multispectral 
optoacoustic tomography. This was achieved by using 
the native fluorescence of DOX and functionalizing 
the hyperbranched polymer with a fluorescent dye 
(Cy-5.5). Finally, a tumour regression study was 
carried out in nude mice bearing MDA-MB-468 
xenografts to determine the efficacy of the targeted 
therapeutic for treating breast cancers. 
Methods 
Materials  
Modified peptide sequences:  N- terminal 
(5-azidopentanoic acid)- YCAYYSPRHKTTF and N- 
terminal (5-azidopentanoic acid)-SPWPRPTY were 
synthesised at the Australian Biobest Biotechnology 
Service. Doxorubicin hydrochloride, trifluoroacetic 
acid (TFA), dicyclohexylcarbodiimide (DCC), 
methacryloyl chloride, tert-butyl carbazate, 
4-dimethylaminopyridine (DMAP), 1-ethyl-3-(3- 
dimethylaminopropyl) carbodiimide hydrochloride 
(EDC·HCl), and 4,4’-azobis(4-cyanopentanoic acid) 
were bought from Sigma Aldrich and used directly 
without any purification. Cyanine-5.5 amine was 
purchased from Lumiprobe. Azobis(isobutyronitrile) 
(AIBN; Sigma Aldrich) was recrystallized twice from 
methanol before use. Solvents including n-hexane, 
ethyl acetate, dichloromethane (DCM), 
dimethylformamide (DMF), diethyl ether, pyridine, 
tetrahydrofuran, acetonitrile and methanol were used 
dry where applicable and of reagent grade quality. 
Poly(ethylene glycol methacrylate) (PEGMA, MW = 
475 g·mol-1) and, ethylene glycol dimethacrylate 
(EGDMA) were purified to remove radical inhibitors 
before use by passing through a basic alumina 
column. Ultrapure water (18.2 MΩ.cm at 25 °C) was 
obtained from an Elga ultra-pure water system.  
Cell culture  
  Trypsin, trypan blue solution, and phosphate 
buffered saline (PBS) were purchased from 
ThermoFisher Scientific. MDA-MB-468 breast cancer 
cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2 in air. Cells were maintained in 
RPMI medium (Gibco) supplemented with 10% (v/v) 
foetal bovine serum (heat inactivated, Bovogen), 100 
U/mL Penicillin, 100 µg/mL Streptomycin and 2 mM 
L-glutamine (Gibco). 
Synthesis of nanomaterials  
  The synthetic pathway and detailed synthesis 
procedure for hyperbranched polymers was 
described in our previous work,[22, 23] and all 
subsequent characterization including 1H NMR and 
UV/Vis for the polymers used in this publication are 
listed in a previous publication.[20] For detection 
purposes, there was one Cy5.5 molecule per ten HBP 
molecules.  
Characterisation of polymeric nanomedicine 
 1H NMR spectra were acquired on a Bruker 
Avance 400 spectrometer. Size distribution and zeta 
potential were measured by Dynamic Light Scatting 
(DLS) at 25 °C. Gel Permeation Chromatography – 
Multiangle Laser Light Scattering (GPC-MALLS) with 
THF as an eluent at a flow rate of 1 mL/min was used 
to measure the molecular weight and dispersity of the 
polymers. 
UV-Vis and fluorescence spectra (Tecan M200 
Infinite pro plate reader) of free DOX and DOX 
incorporated into a representative nanoformulation 
are provided in Figure S5 (25 oC, PBS), showing 
minimal change in spectral properties for the DOX 
under both conditions. 
In vivo anti-tumour efficacy study  
All studies were in accordance with guidelines of 
the Animal Ethics Committee of The University of 
Queensland, and the Australia Code for the Care and 
Use of Animals for Science Purposes. Mice were 
anesthetized with 2% isoflurane in oxygen at a flow 
rate of 2 mL/min. BALB/c nude mice (Australian 
Resources Centre, Australia) were used to establish 
human breast cancer xenografts by injection of 5 × 106 
MDA-MB-468 cells into the left inguinal mammary 
line and tumour growth was monitored by calliper 
measurements twice per week. 
After 2 weeks of cell growth when the tumours 
had reached ~ 100 mm3, in vivo tumour regression 
studies were performed. Six groups were used in the 
study: vehicle control (saline), free DOX, HBP/DOX, 
HBP/A8/DOX, HBP/A13/DOX, HBP/A13 
co-administered with free DOX. In each case, the 
formulations were injected through the tail vein using 
a 29G needle.  To enable comparison of the different 
formulations, with the exception of the saline control, 
each injection contained a dose of 4.5 mg DOX /kg of 




mouse.  Each treatment group consisted of 3 mice 
which were administered twice per week for 4 weeks; 
8 injections in total. The tumour sizes were measured 
using an electronic digital caliper, and the mouse 
body weight was monitored throughout the 
experiment. At the conclusion of the experiments, 
mice were humanely sacrificed on day 30 and the 
tumours were collected for tissue sectioning. The 
tumour volume was calculated using the formula: 
tumour volume = 0.5 × length × width2. The cohort 
number (n=3) was chosen based on power 
calculations to achieve statistical significance in 
tumour regression based on previous studies [12] and 
this is reflected in the significance levels present 
between treatments in Figure 2. 
Ex vivo fluorescence images were acquired using 
a Carestream In-Vivo MS FX Pro (Bruker) imaging 
station with an excitation filter of 630 nm and an 
emission filter of 700 nm for Cy5.5 (190 mm 
field-of-view, f-stop 2.8, 30 s acquisition time) and 
were co-registered with an X-ray image (0.2 mm 
aluminium filter, 1.2 s acquisition time). Live animal 
fluorescence imaging was performed at 2 day 
intervals after injecting each drug formulation into the 
tail vein of each group of mice to monitor 
nanomedicine distribution. 
In vivo multispectral optoacoustic tomography 
(MSOT) 
  For optoacoustic imaging, an MSOT inVision 
256-TF small animal imaging system (iThera Medical, 
Munich, Germany) was used.[24] The mice were 
horizontally positioned in a dedicated holder (iThera 
Medical) under 2% isoflurane anaesthetic and 
wrapped in a thin polyethylene membrane with 
ultrasound coupling gel applied to provide contact 
between the animal and the membrane of the animal 
holder. The mouse was z-translated through the 
imaging plane in 0.5-mm oversampling steps using a 
linear stage control to acquire a stack of 2D axial 
images over the tumour region which in turn allowed 
for optimal three-dimensional (3D) rendering. 10 
frames at each of the following wavelengths were 
acquired in between wavelength-tuning at each 
position in all experiments in this study: 680, 715, 730, 
760, 765, 770, 800 and 845 nm. 
  The images were reconstructed using a 
model-based algorithm and processed using linear 
spectral unmixing to identify the signal of Cy5.5 from 
other intrinsic photoabsorbers, oxy- and 
deoxygenated haemoglobin.[25] All in vivo MSOT 
images presented in the study were scaled to the same 
threshold (Cy5.5: 0–0.15 arbitrary units [au]; oxy- and 
deoxygenated hemoglobin: 0–20.0 au and 0-30.0 au 
respectively; background shown at 845 nm) to enable 
visual comparison of signal intensities throughout. 
After 3D rendering of the acquired stack of 2D 
images, the mean MSOT signal intensities for Cy5.5 in 
the subcutaneous tumour were assessed by setting 
volumes of interest (VOI) around each of the tumours 
at their largest diameter using the ITK-SNAP 
software.[26] 
Ex vivo intratumoural distribution studies 
(Immunofluorescence)  
  Tumours were embedded in Tissue-Tek OCT 
compound, snap frozen in liquid nitrogen and cut into 
7 µm thick frozen sections on glass slides using a 
cryostat. Sections were further prepared with routine 
immunofluorescent methods. Antibodies against 
CD31 (rabbit as host species) were used to stain the 
blood vessels (detection by goat anti-rabbit secondary 
antibody labelled with Alexa568; ex: 568 nm; em: 
500-700 nm). After antibody incubation, sections were 
washed and counter-stained with DAPI. The slides 
were mounted with ProLong Gold and imaged with 
Zeiss confocal microscope using 20× magnification.  
The DOX distribution was acquired using a 488 nm 
excitation filter and a 500-700 nm emission filter.  
Histology studies 
  After the treatment, mice from each group were 
humanely sacrificed and the tumours were collected 
and preserved for routine histology by fixation with 
10% formalin. The fixed tumours were embedded in 
paraffin, sectioned to 5 µm, and stained with 
hematoxylin and eosin (H&E) for tissue histological 
analysis. 
Statistical analysis    
  All experimental data were obtained in 
triplicate unless otherwise mentioned and are 
presented as the mean ± standard deviation. Statistical 
comparison by analysis of variance was performed 
using a Student's t-test and significance levels were 
reported in the text for each analysis. 
Results  
Characterization of the two targeted 
nanomedicines: HBP/A8/DOX or 
HBP/A13/DOX in buffer  
  The targeted nanomaterials were synthesised 
using a previously published procedure and all 
characterisation data is presented in a previous 
publication [20]. The targeting moieties (A13 and A8; 
structure shown in Figure 1) were successfully 
conjugated to the polymer using the copper catalysed 
1,3-dipolar cycloaddition click reaction which was 
validated by complete disappearance of the proton 
resonance at 4.5 ppm from 1H NMR (attributed to the 




methylene resonance adjacent to the alkyne group at 
the polymer chain end). This peak was attributed to 
the methylene protons adjacent to the alkyne group in 
the precursor polymer and its disappearance 
indicated complete cyclisation to yield the product 
leading to ~3.5 aptamers per HBP. This confirmed the 
click reaction proceeded to high conversion and 
indicated that the chosen aptamer was successfully 
attached to each arm of the HBP (Supporting 
information S1). DOX was conjugated to the polymer 
using an acid-labile hydrazone bond in which there 
were approximately six DOX molecules per polymer 
as verified by UV-Vis spectroscopy. The drug was 
shown to release over 24 hours under conditions that 
replicate the pH of endosomes.[20] The 
hydrodynamic radii of the different materials were 
measured using diffusion coefficients calculated from 
1H NMR and correlated to the Stokes-Einstein 
equation which is widely used to determine 
hydrodynamic radii of polymeric particles in 
solution.[27], [28] Finally, the molecular weight was 
measured by GPS-MALLS (Table 1). All 
nanomedicines had hydrodynamic radii between 7-9 
nm. There was no significant change in size between 
HBPs conjugated with A8 or A13.  
Table 1 Physico-chemical properties of polymeric nanomedicine 
 Mn SEC-MALLS (kDa) Dha  (nm) 
HBP/DOXb 34.0 8 ± 2 
HBP/A13 40.2 9 ±  2 
HBP/A8 38.0 9 ± 1 
HBP/A13/DOX 42.0 8 ± 2 
HBP/A8/DOX 41.2 7 ± 1 
aDetermined by NMR diffusion measurements using the Stokes-Einstein equation; b 
ÐM = 1.3, determined by GPC (MALLS) 
Tumour regression studies  
  While in vitro experiments presented in our 
previous study suggested the potential for improved 
therapeutic response of the targeted nanomedicine 
compared with the polymer control, it is important to 
verify these findings in an in vivo model. In this case a 
tumour regression model was chosen to compare the 
efficacy of the nanomedicines that were targeted with 
different aptamers against HSP70 (A8 and A13) and 
the untargeted analogue. Figure 2 shows the relative 
tumour size of MDA-MB-468 human breast cancer 
xenografts in nude mice, indicating therapeutic 
efficacy of five doxorubicin containing formulations 
compared with a PBS control. The formulations 
included DOX conjugated to hyperbranched polymer 
(HBP/DOX), DOX conjugated to hyperbranched 
polymer and targeted with aptamer A13 
(HBP/A13/DOX), DOX conjugated to hyperbranched 
polymer targeted with aptamer A8 (HBP/A8/DOX), 
free DOX co-injected with hyperbranched polymer 
targeted with aptamer A13 (HBP/A13, Free DOX) 
and free DOX. A DOX equivalent dose of 4.5 mg/kg 
was used in each case in order to assess the effect of 
using a nanocarrier to deliver the therapeutic, and 
also to determine whether the different peptides 
showed improved efficacy when used as targeting 
groups on the nanomedicine.  All DOX containing 
formulations showed suppression of tumour growth 
when compared to administration of PBS (Figure 2A). 
In particular, both HBP/A8/DOX and 
HBP/A13/DOX showed statistically significant 
increased inhibition of tumour growth compared to 
either HBP/DOX or DOX alone (p <0.003). This 
indicated that the aptamer displayed either a 
chemo-sensitizing effect when working together with 
doxorubicin to enhance accumulation of DOX in the 
tumour, or a combination of both mechanisms was at 
play. Furthermore, HBP/A13/DOX showed slightly 
higher effectiveness at suppressing tumour growth 
compared to HBP/A8/DOX, which also matches 
previously reported results that show that the 
13-amino acid peptide reproduces the 
HSP70-blocking chaperone and exhibits anti-tumour 
properties in isolation; this is especially evident in 
vivo.13 In addition, both DOX alone and the control 
experiment in which HBP/A13 was co-administered 
with free DOX, showed a similar ability to suppress 
tumour growth.  
  The effects of chemotherapeutic toxicity is 
evident in Figure 2B, where all DOX-conjugated 
polymer treatments (HBP/DOX, HBP/A13/DOX, 
HBP/A8/DOX) show minimal adverse effects in the 
mice, where they exhibit no loss in weight during the 
therapeutic regime compared to the PBS control 
group. In contrast, the treatment group in which free 
DOX was administered in combination with 
HBP/A13 displayed statistically significant weight 
loss (compared to the saline control; p <0.01), with ~ 
20% weight loss over the experimental timeframe. The 
reason for this apparent excessive toxicity compared 
to just free DOX is not known (free DOX treatment 
group showed far lower toxic effect compared to 
saline control), however it may be related to the 
reported sensitising effect of aptamer A13 where 
co-delivery with free DOX enhances this effect in 
functional organs (such as liver, kidney, heart etc.).19 
  Finally, histological images (hematoxylin and 
eosin (H&E) stain; Figure 2C) of tumour sections 
excised from the different treatment groups showed 
that the number of dead cells in the tumours of mice 
treated with both HBP/A8/DOX and 
HBP/A13/DOX are larger compared to that of either 
HBP/DOX or free DOX. This suggests more of an 
efficacious therapeutic effect when the drugs are 
delivered using an aptamer-targeted nanomedicine, 
as opposed to systemic administration of free drug. 





Figure 2 Tumour growth inhibition of s.c human breast MDA-MB-468 carcinoma xenografts in BALB/c nude mice. Mice were injected i.v. with 4.5 mg/kg DOX 
equivalent dose: Saline, free DOX, HBP/DOX, HBP/A8/DOX, HBP/A13/DOX, HBP/A13&free DOX. (A) Tumour volume change and (B) body weight change (n=3) 
Values are the means and error bars the standard deviations (n=3, S.D.) (*p<0.003, **p<0.004, ***p<0.01). (C) Representative histological images (H&E stained) of 










Figure 3 Quantitation of optical images of blood and tissues (tumour, liver, heart, spleen, lung and kidney) after i.v. administration (4.5 mg/kg DOX equivalent dose) 
of different drug formulations against s.c. human breast MDA-MA-468 carcinoma xenografts. Mice were sacrificed at 48 h after last treatment. (A) DOX fluorescence 
intensity level in blood and other organs. (B) Cy5.5 (polymeric carriers) fluorescence intensity level in blood and other organs. Values are the means ± the standard 
deviations (n=3, S.D.) (*p<0.0001, **p<0.05, ***p<0.2). 
 
Ex vivo Biodistribution  
  The relative distribution of the different 
components in the major organs of the mice were 
measured by ex vivo fluorescence imaging of excised 
organs at 48 hrs post-injection of the final treatment. 
Relative fluorescence intensity of free DOX and DOX 
loaded HBPs in blood and different organs (tumour, 
liver, heart, kidneys, lungs and spleen) is shown in 
Figure 3.    
Figure 3A clearly shows that the mice treated 
with aptamer-targeted formulations (HBP/A8/DOX, 
HBP/A13/DOX) led to significantly increased DOX 
accumulation in the tumour at this time point 
compared to HBP/DOX (~ 2.6-fold increase; p < 
0.0001), HBP/A13 co-delivered with free DOX or free 
DOX alone (~5-fold increase; p <0.0001). Specifically, 
the accumulation of DOX in the tumours by 
HBP/A13/DOX was approximately 5.5 times higher 
compared to free DOX after 28 days treatment, and 
HBP/A8/DOX was at approximately 5 times higher 
levels. In the absence of any significant self-quenching 
of the fluorophores, these differences were attributed 
to enhanced accumulation of the polymers in the 
tumour tissue as a function of the aptamer binding to 
HSP70 on the tumour cells.  It is also evident from the 
Cy5.5 channel (which is a measure of the nanocarrier 
accumulation) that there was no significant difference 
in HBP accumulation between the HBP/A8/DOX, 
HBP/A13/DOX, in line with the DOX distribution. 
The differences in distribution between organs 
between polymer signal and DOX signal can most 
likely be attributed to the gradual clearance of 
polymer from the tumour environment over the time 
course of the therapy (while DOX most likely remains 
bound tightly to oligonucleotides within the nuclei of 
the cells as is often observed in vitro). Most 
importantly for downstream application of these 
nanomedicines, DOX concentration in the heart 
typically showed statistically-significant reduction in 
accumulation for the HBP/A8/DOX, HBP/A13/DOX 
groups compared to treatment groups when free DOX 
was administered (again, either as free DOX or as a 
combination therapy with HBP/A13; p<0.05); DOX is 
known to cause cardiotoxicity when administered 
alone.[2], [3]  
Intra-tumoral distribution of nanomedicine 
within xenografts  
  To provide detailed information on the 
distribution of nanomedicine (and DOX) within the 
tumour microenvironment and to assess whether the 
diffusion of both nanocarrier and/or drug into 
tumour tissue affects efficacy, fluorescence imaging of 
tumour slices at the completion of the treatment study 
was undertaken. Figure 4 shows representative 
fluorescence images of slices of the xenografted 
tumours from each treatment group that highlight the 
perivascular distribution of the native fluorescence of 
doxorubicin (green), the polymeric carrier labelled 
with cyanine5.5 (red) and the cell nuclei that have 
been stained with DAPI (blue)) in relation to 
anti-CD31 stained blood vessels (orange). Looking 
first at the free DOX treatment group, the DOX 
channel shows a relatively weak signal, which is 
distributed uniformly throughout the slice. The 
HBP/DOX treatment group exhibits strong signals 
from the polymer carrier (red) that are predominantly 
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co-localized or adjacent to tumour blood vessels 
(orange) and a weaker signal that is distributed more 
uniformly throughout the tumour. In contrast, the 
DOX signal (green) was distributed throughout the 
slice and not significantly co-localised around the 
blood vessels (yellow). The regions where there is a 
lack of co-registration (at least in intensity of signal) 
between the DOX and polymer signals demonstrate 
that drug release is occurring from the carriers and the 
higher DOX signal for the HPB/DOX compared to the 
free DOX treatment groups suggests that enhanced 
accumulation of nanomedicine (and drug) occurs in 
this xenograft model compared to the drug alone. The 
targeted therapeutics, HPB/A8/DOX and 
HBP/A13/DOX treatment groups exhibit similar 
distribution profiles to the HBP/DOX.  Again, the 
regions that lack co-registration of the polymer and 
DOX signals show that drug release is occurring in the 
tumour environment. Finally, the HPB/A13 that was 
co-delivered with the free DOX treatment group 
shows co-localisation of the polymer with the blood 
vessels, and a weak uniform distribution of DOX, 
similar to that observed for the free DOX case. 
In order to better analyse these images, intensity 
plots of fluorescence signal were generated across the 
tumour slice to investigate the relationship between 
fluorescence intensity of DOX and the polymeric 
carrier, and to understand how this relates to 
diffusional distance from blood vessels. The 
comparison between groups showed that both 
targeted HBP/A8/DOX and HBP/A13/DOX showed 
higher DOX distribution throughout the tumour mass 
(maximum intensity on the y-scale in supporting 
information Figure S2) compared to the other three 
untargeted groups (DOX, HBP/DOX and HBP/A13 
co-delivered with free DOX) where weaker DOX 
signals were observed.  Moreover, in these cases, the 
large carriers appear to have a significant proportion 
of the signal remaining very close to the vessel wall 
(only penetrating a few cells distances into the tumour 
tissue), while the smaller size of DOX released from 
the polymeric carriers appears to diffuse throughout 
 
Figure 4 Distribution within tumour slices of doxorubicin (green) and polymer (red) in relation to tumour blood vessels (orange) and cell nuclei (blue). Scale bar 
= 100 μm 











the tumour matrix. This is presumably due to the 
hydrophilic nature of DOX as well as its much smaller 
size compared to the nanomedicine, leading to a 
diffusion front of drug that penetrates well into the 
tumour microenvironment. This is probably most 
evident for the targeted systems using Aptamer 13, 
where there is significant accumulation within the 
region of the blood vessel. Nonetheless, the signal 
assigned to the nanomedicine (Cy-5.5) is still able to 
effectively distribute throughout the tumour to some 
extent in all treatment groups (albeit to a lesser extent 
than the DOX once it is released).  
In vivo MSOT imaging of targeted and 
untargeted nanomedicines in live animals  
  MSOT is a relatively new technique that allows 
monitoring of both endogenous (e.g. haemoglobin) 
and exogenous probes.[29], [30] It has been reported 
that many tumour microenvironment properties such 
as tumour type, size and stage could affect the 
penetration of nanoparticles,[31] and that the 
effectiveness of chemotherapeutics could be 
influenced by their distribution through the 
tumour.[32]  In order to better understand how the 
different treatments can distribute through the 
tumour microenvironment, MSOT was used to 
investigate how accumulation within the tissue was 
related to the vasculature in living animals. The 
strong vascular accumulation of the nanomedicines 
(independent of whether they were targeted or not), 
suggested that there was preferential accumulation 
close to blood vessels within the tumour. To better 
demonstrate the in vivo accumulation of 
HBP/A13/DOX compared to HBP/DOX, MSOT 
images were acquired of live mice during weeks 3 and 
4 of the therapeutic regime to determine whether a 
noticeable change in polymer distribution could be 
observed which might give an indication on any 
improvements in targeting efficiency of the aptamer 
system. The images in Figure 5 show the long-term 
accumulation during weeks 3 and 4 of the 
Cy5.5-labelled HBP/DOX and HBP/A13/DOX 
(green) with respect to the endogenous signals of oxy- 
and deoxyhemoglobin (HbO2 (red) and Hb (blue), 
respectively [33]) within the tumour volumes. Note 
that DOX is undetectable by this technique owing to 
the low wavelength of absorption (absorption cutoff is 
550 nm) and the enhanced signal around the mouse 
image in the targeted experiment was due to artefacts 
whose origin has been previously reported.[34, 35] In 
both the HBP/DOX and HBP/A13/DOX, higher 
nanocarrier accumulation was observed in the tumour 
tissue compared to the PBS control, although a much 
higher signal was evident in the targeted 
nanomedicine. MSOT further allows in vivo 
quantification of signal accumulation and Figure 5C 
highlights an approximately 5-fold increase in 
accumulation of the targeted nanomedicine 
(HBP/A13/DOX) compared to the untargeted system 
(HBP/DOX). As was observed in the ex vivo analyses 
presented in Figures 4 and supporting information 
Figure S2, the localisation of the Cy5.5-labelled 
polymers was noted to have a vascular-dependent 
distribution, where the polymer appeared (at least on 
the resolution of this imaging modality) to be close to 
blood vessels or pools in the tumour (Figure 5A and 
5B) as a consequence of slow diffusion away from 
blood vessels into the tumour tissue. 
Conclusion and summary 
  This report has demonstrated the effective 
inhibition of xenograft tumours in mice when treated 
with a number of therapeutic formulations. Both 
HBP/A8/DOX and HBP/A13/DOX showed 
significant inhibition of tumour growth, which 
supports the previous report that these aptamers act 
as antagonists for HSP70 in cancer cells. By utilising 
the specificity for HSP70, the aptamer targeted 
polymers can therefore provide a means to 
significantly enhance accumulation of 
nanotherapeutics within tumour tissue; in the case of 
this study, this led to significantly enhanced DOX 
levels in the tumour microenvironment. Free DOX 
showed some degree of effectiveness in leading to a 
regression in tumour volume, but histological 
analyses clearly show the greater efficiency in 
accumulation of therapeutics when using the targeted 
formulations compared to those that were untargeted. 
We propose that the use of the peptide aptamer to 
bind to HSP70 not only led to higher accumulation, 
but also longer retention at the site of the tumour 
presumably because of the ligand-receptor 
interaction.  
There were no significant adverse health 
conditions observed in any of the treatment groups 
where doxorubicin was conjugated to polymer 
(HBP/DOX, HBP/A13/DOX and HBP/A8/DOX). 
This indicated that conjugation of DOX via a 
hydrazone bond was significantly stable in circulation 
such that systemic levels of the drug did not reach a 
level where toxicity was observed. Conversely, mice 
that were exposed to the combination treatment of 
HBP/A13 with free DOX showed significant weight 
loss, perhaps due to the HBP/A13 conjugate acting as 
an antagonist for HSP70 that is active in cancer cells 
and also healthy cells. The ex vivo biodistribution 
result further validated the observation that A13 and 
A8 lead to almost the same level of tumour targeting 
efficacy. It was observed from the tumour regression 
study that HBP/A13/DOX showed slightly improved 




tumour inhibition compared to HBP/A8/DOX. This 
may be related to previous observations that A13 has 
improved chemosensitizing effects compared to 
A8,[19] and when combined with a chemotherapeutic 
drug this effect is exacerbated in a synergistic fashion. 
Nonetheless, both formulations showed effective 
treatment of the disease.  
MSOT images of mice treated with aptamer 
targeted nanomaterials resulted in an enhanced 
uptake in the tumour volume compared to untargeted 
polymer. A combination of both ex vivo fluorescence 
imaging and MSOT imaging showed that the 
distribution of the HBP nanomedicines in solid 
tumours only occurred to a low extent. Contrastingly, 
the ex vivo analyses show that both high tumour 
accumulation and efficient intra-tumoural diffusion of 
DOX occurs for HBP/A8/DOX and HBP/A13/DOX. 
This implies that in terms of developing new nano 
therapeutics for delivery of DOX to solid tumours, the 
penetration of the nanomedicine may not be a critical 
factor. Rather, mechanisms for increasing tumour 
microenvironment accumulation, as well as efficient 
release of the DOX is more important for treating the 
tumours since the DOX appears to effectively diffuse 
independently into tumour tissue.   
 
Figure 5 (A) Representative in vivo transverse MSOT images of mice at the largest cross-section point of each tumour (circled in white) in mice treated with 
HBP/DOX, HBP/A13/DOX and PBS during the 3rd and 4th weeks of treatment. Spectrally unmixed MSOT signal from accumulated Cy5.5 (green, 0-0.15 a.u.) can be 
seen with respect to blood vessels through spectral unmixing of signal from oxygenated (red, 0-20 a.u.) and deoxygenated haemoglobin (blue, 0-20 a.u.) overlayed on 
a single wavelength illumination at 845 nm (greyscale). All spectra used for signal unmixing can be found in the supporting information (Figure S4) A magnification of 
the tumour volume of the mouse treated with targeted polymer after 4 weeks is shown in B. (C) Comparison of the mean Cy5.5 signal in each tumour volume clearly 
shows the highest accumulation in the targeted HBP/A13/DOX mouse. Error bars indicate the variation in signal intensity between images acquired 1 week apart in 
a single mouse. 




   In conclusion, these results demonstrate that 
both A8 and A13 significantly enhance the 
accumulation efficiency of HBP-based nanomedicines 
in vivo and offer new avenues for exploring 
nanomedicine treatments for cancer.  
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